Financial stocks rocketed higher following Donald Trump winning the U.S. presidential election. The S&P 500 Financials Sector ...

Driven by those combined issues, the stock soared 10.3% as of 11:55 a.m. ET -- huge gains for the country's No. 1 bank by assets. The financials sector as measured by the Financial Select Sector SPDR ...

Individual stock exposure can also deviate only within a 1-percentage-point range. JPMorgan equity analysts forecast earnings for each eligible stock using a dividend discount model, incorporating ...

JPMorgan Chase has navigated the rising-interest-rate environment exceptionally well. Under CEO Jamie Dimon, the bank has performed well, thanks to its approach to risk and balance-sheet management.

JPMorgan To Lay Out $151 Million In Penalties, Investor Payments After SEC Flags 'Various Law Violations' (UPDATED) The SEC charged JPMorgan in five separate enforcement actions for failures ...

JPMorgan Chase & Co. may be the best bank in its class, but its stock price is too expensive and it’s a good time to take profits, Baird analyst David A. George said in a research note. George ...

JPMorgan Chase & Company JPM stock can hit new highs in 2024 because the fear induced by September’s guidance warnings was misplaced, the Q3 results were better than expected, cash flow and ...

Over the past year, JPMorgan Chase (JPM) stock has risen 56% (see chart below), propelling the company to the top spot among publicly traded banks with a market capitalization of $634.4 billion.

With the gains in JPMorgan's stock accelerating after the opening bell, it was now on track to close at the 2nd-highest price ever, based on available FactSet data back go January 1972.

Logan Group and KWG Group Holdings signed a US$1.05 billion refinancing deal arranged by JPMorgan to roll over a loan due on August 25, sources said.

On Tuesday, JPMorgan adjusted its stance on Neumora Therapeutics (NASDAQ: NMRA), downgrading the stock from Overweight to Neutral and lowering the price target to $15.00 from the previous $18.00.

On Monday, JPMorgan adjusted its stance on shares of Ageas, a multinational insurance company, raising the stock from Underweight to Neutral. The firm also increased its price target for Ageas ...